Overview
- The companies announced the offer on Monday, July 20, 2026, with Samsung proposing SFr44.31 per share for PolyPeptide in a SFr1.46 billion all-cash takeover bid.
- PolyPeptide's board unanimously recommended shareholders accept the offer and its largest shareholder, Draupnir Holding, has committed to tender its roughly 55.65% stake.
- Samsung expects the public tender to launch by the end of August or mid-September and to close by year-end subject to Swiss takeover rules, regulatory approvals and minimum acceptance conditions.
- The deal would give Samsung six PolyPeptide production sites across Europe, India and the U.S., adding peptide development and manufacturing capacity seen as vital for fast-growing GLP‑1 obesity and diabetes drugs.
- Samsung said it will seek a squeeze-out of remaining minority shares and delist PolyPeptide after closing, a move that would make PolyPeptide a wholly owned unit and could reshape CDMO competition and client relationships in peptide therapeutics.